The University of Virginia is participating a clinical research study for adults ages 18 and over, who have newly diagnosed ovarian, fallopian tube or peritoneal carcinoma and you are going to be treated with neoadjuvant chemotherapy followed by interval surgery. If you decide to participate in this study, you will be asked to spend about 4-5 months on this study. You will be randomized to either aspirin or a matching placebo but all patients will receive standard chemotherapy.
The purpose of this research study is to:
• Evaluate the effectiveness of aspirin along with neoadjuvant chemotherapy in decreasing markers of immune suppression in the tumor at interval debulking surgery;
• Evaluate the effectiveness of aspirin for reducing tumor burden and changing tumor marker expression;
• Examine the effectiveness of aspirin for reducing plasma inflammatory markers and CA-125, a protein in your blood, and changing other blood markers.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT05080946
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.